Pharsight

Lotemax Sm generic

Lotemax Sm is an ophthalmic drug owned by Bausch And Lomb Inc. that contains loteprednol etabonate. It was first authorized for market use on 22nd February, 2019 and is available in gel form.

When will Lotemax Sm generic be available?

The generic version of Lotemax Sm is expected to be released on or after 23rd December, 2036 after the expiry of its final patent. This generic release date is based on the expiration of the company's last patent on the drug.

Lotemax Sm uses

Lotemax Sm is used in the treatment of post-operative inflammation and pain following ocular surgery. Its active ingredient, loteprednol etabonate, contributes to its effectiveness.

Lotemax Sm patent expiration

Lotemax Sm is covered by two patents. The most recent of these patents will expire on 23rd December, 2036 - this marks the earliest potential date for the release of a Lotemax Sm generic. Below are the details of the patent:

EPO Oppostions filed on Lotemax Sm

Litigations filed on Lotemax Sm

Lotemax Sm dosage

Want to ask something?